The company will use the award to research and develop a surface-modified tibial intramedullary nail combining the Semprus Sustain technology with antimicrobial technology. The company could receive up to $2.46 million in funding for the project under the award.
Teleflex will conduct the research in Cambridge, Mass., in conjunction with the U.S. Army Institute for Surgical Research at Fort Sam Houston in San Antonio. TATRC previously granted $1.1 million to Semprus BioSciences in 2011 to develop orthopedic devices designed to reduce biofilm formation.
More articles on orthopedic devices:
10 key points on minimally invasive SI joint fusion: 5-year data
Orthopaedic Implant Company launches anatomic lower extremity & straight plates
Aurora Spine, MedAssets enter into contract
